Based in London, Ternary Therapeutics was founded by experienced drug hunters who helped pioneer targeted protein degradation and the application of AI in drug discovery. Ternary’s platform integrates advanced AI models with molecular dynamics simulations to rationally design molecular glues that do not require a pre-existing druggable site on either protein, overcoming a major limitation of conventional approaches.
Ternary Therapeutics: Venture Capital Funding History
Ternary Therapeutics
Ternary Therapeutics
- Life Sciences
- London, United Kingdom
- £3.6m
- ternarytx.co.uk
- Update Information
More venture news
- 7 Oct 2026

Cori ClinicalCori Clinical unlocks a £3m seed round led by Breega for an AI workspace improving clinical trial design
SeedLife Sciences - 23 Sept 2026

Basecamp ResearchBasecamp Research unlocks £105m Series C led by S32 to design medicines with frontier AI models
Series CLife Sciences - 18 Sept 2026

Big Picture BioBig Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies
Pre-seedLife Sciences
